Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Extends RLS Franchise With Gabapentin Prodrug Through XenoPort Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

XP13512 is in Phase III development for restless legs syndrome and Phase II for neuropathic pain.
Advertisement

Related Content

FDA Wants Solzira Restless Legs Data Reformatted
FDA Wants Solzira Restless Legs Data Reformatted
GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug
GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug
GSK/XenoPort Next-Generation RLS Drug Shows Efficacy In Phase III
GSK Plans Next-Generation Restless Legs Treatment Filing In Q3 2008
GSK 14-Hour Requip CR “Approvable,” FDA Says
GSK/XenoPort Prep RLS Candidate For Phase III In Neuropathic Pain
GSK Predicts Significant Restless Legs Market For Requip
GSK Predicts Significant Restless Legs Market For Requip

Topics

Advertisement
UsernamePublicRestriction

Register

PS065718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel